State of play and outlook

Transcription

1 Health in Horizon 2020 State of play and outlook European High level meeting Madrid, 2 nd October 2012 Didier Gambier, Head of the Horizontal Aspects Unit, Health Directorate Directorate-General for European Commission

2 FP7 Health state of play 3.3 billion EUR curently invested in 713 ongoing projects Some 2,900 organisations from 122 countries involved Leading role in 6 international research consortia 1 billion EUR investment in Europe's largest public-private initiative for better and safer medicines

3 Big budgets big impacts 1,210 projects funded 4.9 billion euros invested 14,000 teams 114 countries ~50% of projects on-going 70,000 PubMed publications 50,000 high-skilled jobs 23.3% 3% listed on patent application(s) 17% envisage creating a SME 7.4% created one or more SMEs

4 Publicly funded research: EU vs. US Low coordination/ high fragmentation, invest less than the US Brain disease Dementia Alzheimer Cancer Medium coordination/ fragmentation, invest less than the US Towards joint programming in research Working together to tackle common challenges more effectively, EU COM (2008) 468

5 Mastering key challenges Cancer, chronic and degenerative diseases gain importance in the context of the ageing population More than 70% of healthcare spending on chronic diseases Wanted: ways of keeping our healthcare costs stable and our healthcare systems running EU must catch up with global health innovation leaders and keep its biomedical industry

6 Setting sail for Horizon 2020 Europe needs cutting edge research and innovation Essential to ensure competitiveness, growth and jobs Vital to tackle pressing societal challenges 3% of GDP invested in R&D: headline target of Europe 2020

7 More money for health h research in times of austerity? Investing into the right research pays off: Simpler, more personalised and costefficienct technologies and treatments Fewer chronic patients New technolgies, companies and markets Higher share of radical innovation Large returns on investment New skilled jobs in high value-added sectors

8 Health, Demographic change & wellbeing - the Commission's proposal for Horizon 2020 Understanding health determinants Improving health promotion & disease prevention Developing effective screening programmes Improving the assessment of disease susceptibility Improving surveillance and preparedness Understanding disease Developing better preventive vaccines Improving diagnosis Using in-silico medicine for improving disease management and prediction Treating disease Transferring knowledge to clinical practice and scalable innovation actions Better use of health data Improving support for policy-making and regulation Active ageing, independent and assisted living Individual empowerment for selfmanagement of health Promoting integrated care Optimising the efficiency and effectiveness of healthcare systems Reducing inequalities through evidence based decision making Dissemination of best practice, and innovative technologies and approaches.

9 Collaborative projects Simpler Simpler programme architecture, a single set of rules Easy to use cost More inclusive reimbursement model: one More support for unique funding rate Less paperwork in preparing proposals Reduce time to grant by 100 days innovation and activities close to the market Strong focus on creating business opportunities

10 Special support for SMEs ~5 billion EUR Inspired by the US model "SBIR" Challenge driven, bottom up A single company can be funded 3 phases / 3 entry points: Concept and feasibility assessment R&D, demonstration, market replication Commercialisation

11 In the pipeline: public-private private partnership for innovative health research Based on the successes of the Innovative Medicines Initiative (IMI) Legislative proposal only after Horizon 2020 approval Organisation and structure to be defined Your view matters - public consultation until 4 October on ience_h2020/consultation_en.htm htm

12 Key Figures of 37 on-going g Projects 603 million EUR IMI JU cash contribution 508 Academic & research teams 17 patient org 92 SMEs 10 regulators 341 EFPIA teams 600 million EUR EFPIA in kind contribution EU-AIMS contribution to autism ~ 3500 researchers > 200 publications etox contribution to cardiotoxicity

13 Renewal of the "European and Developing Countries Clinical i l Ti Trials Partnership" (EDCTP) Public-public partnership to fund CT in HIV/AIDS, TB, malaria and Neglected Infectious Diseases Strategic Business Plan to ensure critical level of commitment to EDCTP2 Plans to keep scope and mandate Proposal for EU legislation on EDCTP2 co-funding under development High-Level Conference in Cape Town, 5 Nov 2012 Current Partnership

14 Continued international ti cooperation International Human Metagenome Consortium International K.O. Mouse Consortium International Rare Disease Research Consortium International Cancer Genomics Consortium Int. Initiative for Traumatic Brain Injury Research rt tguest/fotolia.com International Human Epigenome Consortium

15 European Partnership on Active and Healthy Ageing Objective: increase the healthy lifespan of EU citizens by 2 years by 2020 Connects and engages the main players within and outside EU institutions Partners made already more than 250 concrete commitments First conference of interested partners on 6 November 2012 ec.europa.eu/active-healthy-ageingeuropa eu/active ageing

16 Thank you!